Data demonstrating the in vivo anti-tumor efficacy of thermosensitive liposome formulations of a drug combination in pre-clinical models of breast cancer

Description

The dataset expands on previously published data that described the development of a thermosensitive liposome formulation of the heat shock protein 90 inhibitor alvespimycin (ThermoALV), in vitro characterization of the combination effects of alvespimycin (ALV) and doxorubicin (DXR) in a panel of breast cancer cell lines, as well as the in vivo distribution of the drugs following administration in thermosensitive liposomes in combination with mild hyperthermia in MDA-MB-231 tumor bearing female SCID mice (https://doi.org/10.1016/j.jconrel.2019.06.012). Here the combination effects of DXR and ALV are characterized in the murine breast cancer cell line 4T1 under conditions of mild hyperthermia. In addition, the therapeutic efficacy and treatment associated toxicity of this thermosensitive liposomal combination are evaluated in both immunocompromised and immunocompetent mouse breast cancer models.

Steps to reproduce

4T1 cells were treated with DXR and/or ALV at either 37 or 42 °C. Combination indices were calculated by CalcuSyn Version 2.0 based on cell viability results from acid phosphatase assay. Tumor volume, animal weight, and survival data were measured every other day following treatment of mice with thermosensitive liposome formulations in combination with mild hyperthermia.

Institutions

Categories

Funding

Licence